Selected article for: "successful vaccine and vaccine efficacy"
Author: Cody S. Nelson; Tori Huffman; Eduardo Cisneros de la Rosa; Guanhua Xie; Nathan Vandergrift; Robert F. Pass; Justin Pollara; Sallie R. Permar
Title: HCMV glycoprotein B subunit vaccine efficacy was mediated by non-neutralizing antibody effector functions
  • Document date: 2018_1_11
    • ID: bxqc9a7f_5
    Snippet: The glycoprotein B (gB) + MF59 adjuvant subunit vaccine platform is the most successful 31 HCMV vaccine tested to-date, demonstrating approximately 50% efficacy in preventing HCMV 32 acquisition in phase II trials. However, the mechanism of vaccine protection remains unknown......
    Document: The glycoprotein B (gB) + MF59 adjuvant subunit vaccine platform is the most successful 31 HCMV vaccine tested to-date, demonstrating approximately 50% efficacy in preventing HCMV 32 acquisition in phase II trials. However, the mechanism of vaccine protection remains unknown.

    Search related documents:
    Co phrase search for related documents
    • adjuvant subunit and vaccine platform: 1, 2
    • adjuvant subunit and vaccine protection: 1, 2, 3, 4, 5, 6
    • adjuvant subunit and vaccine protection mechanism: 1
    • adjuvant subunit vaccine platform and hcmv vaccine: 1
    • adjuvant subunit vaccine platform and vaccine platform: 1
    • adjuvant subunit vaccine platform and vaccine protection: 1
    • adjuvant subunit vaccine platform and vaccine protection mechanism: 1
    • date test and vaccine protection: 1
    • hcmv vaccine and vaccine platform: 1
    • hcmv vaccine and vaccine protection: 1, 2
    • hcmv vaccine and vaccine protection mechanism: 1
    • phase II trial and vaccine platform: 1
    • phase II trial and vaccine protection: 1, 2
    • unknown remain and vaccine protection: 1